Study of the chronic toxicity of anticancer treatments in patients with localised breast cancer – cognitive section and ancillary imaging study.
Coordinator: Lange M, Leger I
Background: There are many mechanisms that may be involved in cognitive impairment (e.g., direct chemotherapy toxicity, concomitant treatment toxicity, anxiety and/or depression, fatigue, hormones, physiological parameters and genetic polymorphisms). However, these have not yet been totally identified. In addition to the behavioural cognitive study (neuropsychological tests), the imaging study provided additional information on the anatomical correlates of the observed cognitive impairment to better understand their onset.
Objectives: The objective of this longitudinal study is to assess the relationships between these cognitive disturbances and brain abnormalities in patients receiving treatment for breast cancer. Several secondary objectives will be studied: evaluation of the incidence of the onset of brain abnormalities following anti-cancer treatments, analysis of the correlations between brain abnormalities and subjective cognitive complaints.
Study methodology: This is a non-randomised, multicenter longitudinal study. Patients will be selected from the CANTO study cohort.
Current study status: 513 inclusions (closed), including 41 with imaging, follow-up ongoing (439 post-treatment, 309 at 12 months, 75 at 36 months), 150 healthy subjects.
Collaboration: Unicancer Promotion
Sponsor: Agence Nationale de la Recherche (ANR), ancillary imaging study: Prix Ruban Rose Qualité de Vie 2013